Home » Stocks » TIL

Instil Bio, Inc. (TIL)

Stock Price: $22.03 USD -0.21 (-0.94%)
Updated Apr 9, 2021 4:00 PM EDT - Market closed
After-hours: $23.13 +1.10 (4.99%) Apr 9, 4:45 PM
Market Cap 2.77B
Revenue (ttm) 138,000
Net Income (ttm) -37.74M
Shares Out 125.81M
EPS (ttm) -0.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 9
Last Price $22.03
Previous Close $22.24
Change ($) -0.21
Change (%) -0.94%
Day's Open 22.22
Day's Range 21.45 - 23.25
Day's Volume 122,214
52-Week Range 21.44 - 29.49

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

DALLAS, March 23, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies f...

2 weeks ago - GlobeNewsWire

Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...

Other stocks mentioned: AFCG, CNTB, FNCH, GANX, JWEL, NAPA, OLO ...
2 weeks ago - Benzinga

DALLAS, March 18, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies f...

3 weeks ago - GlobeNewsWire

Instil Bio, an early stage biotech developing cell therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

1 month ago - NASDAQ

Instil Bio, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

About TIL

Instil Bio is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. Using our optimized and scalable manufacturing process, we are advancing our lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. We plan to submit an investigational new drug application, or IND, to the FDA, and, if authorized to proceed, initiate a Phase 2 trial in the second half of 2021. We plan to ... [Read more...]

Industry
Biological Products
IPO Date
Mar 19, 2021
CEO
Bronson Crouch
Employees
150
Stock Exchange
NASDAQ
Ticker Symbol
TIL
Full Company Profile

Financial Performance

Financial Statements